SCHEMBL361541

SCHEMBL361541

N#Cc1ccc([N+](=O)[O-])cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 3/20 0.59
GPR35 Q9HC97 3/20 0.56
ALDH1A1 P00352 6/20 0.54
GAA P10253 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 2/20 0.54
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.54
TSHR P16473 3/20 0.52
HPGD P15428 2/20 0.52
MAPK1 P28482 2/20 0.52
TP53 P04637 1/20 0.52
LMNA P02545 4/20 0.51
THRB P10828 1/20 0.50
ERN1 O75460 1/20 0.47
RECQL P46063 2/20 0.46
ALOX15 P16050 2/20 0.44
XDH P47989 1/20 0.44
KDM4E B2RXH2 1/20 0.43
TTR P02766 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342722 0.85 VCAM1 (0.64) VCAM1GPR35ALDH1A1GAASMN1; SMN2
SCHEMBL31227792 0.85 VCAM1 (0.64) VCAM1GPR35ALDH1A1GAASMN1; SMN2
SCHEMBL17502093 0.84 ALDH1A1 (0.57) VCAM1ALDH1A1GAASMN1; SMN2MEN1
SCHEMBL17502094 0.84 ALDH1A1 (0.57) VCAM1ALDH1A1GAASMN1; SMN2MEN1
SCHEMBL5187586 0.83 GPR35 (0.58) VCAM1GPR35ALDH1A1GAASMN1; SMN2
SCHEMBL1980405 0.82 MEN1 (0.52) VCAM1ALDH1A1GAASMN1; SMN2MEN1
SCHEMBL73860 0.82 VCAM1 (0.70) VCAM1ALDH1A1GAASMN1; SMN2MEN1
Fluoride SCHEMBL28259583 0.81 VCAM1 (0.68) VCAM1ALDH1A1GAASMN1; SMN2MEN1
SCHEMBL82629 0.79 VCAM1 (0.66) VCAM1GPR35ALDH1A1GAASMN1; SMN2
Carbamic Acid SCHEMBL29158325 0.78 VCAM1 (0.55) VCAM1GPR35ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138974-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS LEUKOS BIOTECH S L (ES) 2026-05-21 US disclosed
US-12540133-B2 Potent and selective compounds as serotonin 1B receptor modulators LEUKOS BIOTECH, S.L. (ES) 2026-02-03 US disclosed
EP-4445901-A2 NEW POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS Leukos Biotech, S.L. (ES) 2024-10-16 EP disclosed
EP-4225753-B1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS LEUKOS BIOTECH S L (ES) 2024-07-31 EP disclosed
US-20240166639-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS LEUKOS BIOTECH, S.L. (ES) 2024-05-23 US disclosed
CN-116635390-A Potent and selective compounds as serotonin 1B receptor modulators 莱科斯生物技术公司 2023-08-22 CN disclosed
EP-4225753-A1 POTENT AND SELCTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS Leukos Biotech, S.L. (ES) 2023-08-16 EP disclosed
CN-111601807-B Exo-azaspiro inhibitors of MENIN-MLL interactions 詹森药业有限公司 2023-03-31 CN disclosed
US-20230039917-A1 EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2023-02-09 US disclosed
US-11396517-B1 Exo-aza spiro inhibitors of menin-MLL interaction JANSSEN PHARMACEUTICA NV (BE) 2022-07-26 US disclosed
EP-1144373-A3 SERINE PROTEASE INHIBITORS Genentech, Inc. (US) 2002-01-02 EP disclosed
EP-1149069-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
EP-1144373-A2 SERINE PROTEASE INHIBITORS Genentech, Inc. (US) 2001-10-17 EP disclosed
US-6242644-B1 FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS HOFFMANN-LA ROCHE INC. 2001-06-05 US disclosed
US-20010001799-A1 N-(4- carbamimidoyl-phenyl) -glycine derivatives ACKERMANN JEAN (CH) 2001-05-24 US disclosed
US-6140353-A USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 2000-10-31 US disclosed
WO-2000041531-A2 SERINE PROTEASE INHIBITORS GENENTECH, INC. (US) 2000-07-20 WO disclosed
WO-2000035858-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed
EP-0921116-A1 N-(4-carbamimido-phenyl)-glycine amide derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-06-09 EP disclosed
EP-0271323-A2 Dye forming coupler and photographic element containing same EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1988-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138974-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS HTR3B, HTR1B, HTR1A VCAM1 1023/4885GPR35 191/4885ALDH1A1 1180/4885
US-12540133-B2 Potent and selective compounds as serotonin 1B receptor modulators HTR3B, HTR1A, HTR1B VCAM1 802/4885GPR35 187/4885ALDH1A1 1283/4885
US-20240166639-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS HTR1B, HTR1A, HTR3B VCAM1 740/4885GPR35 59/4885ALDH1A1 793/4885
US-11396517-B1 Exo-aza spiro inhibitors of menin-MLL interaction BMI1, MLLT1, EED VCAM1 673/4885GPR35 4208/4885ALDH1A1 2583/4885
US-20010001799-A1 N-(4- carbamimidoyl-phenyl) -glycine derivatives GLRA1, NGLY1, GLS VCAM1 3987/4885GPR35 1941/4885ALDH1A1 2850/4885
US-20230039917-A1 EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION BMI1, MLLT1, SUZ12 VCAM1 622/4885GPR35 4135/4885ALDH1A1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.